Capital Advisors Ltd’s Altimmune ALT Stock Holding History

Capital Advisors Ltd’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-43	Closed	-$1K	–	1185
2022 Q4	$1K	Hold	43	–	–	﹤0.01%	933
2022 Q3	$1K	Hold	43	–	–	﹤0.01%	946
2022 Q2	$1K	Buy	+43	New	+$265	﹤0.01%	710

Other funds holding ALT

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Capital Advisors Ltd's ALT Position: Q1 2023 in Review

Capital Advisors Ltd sold out of Altimmune (ALT) in Q1 2023, closing a stake of 43 shares — an estimated $1K sold.

Capital Advisors Ltd first reported a position in ALT in Q2 2022 and held it in 3 quarters. The position peaked at $1K in Q4 2022. 132 funds tracked by Wall St. Rank hold ALT as of Q1 2023.

Capital Advisors Ltd reported no remaining Altimmune position as of Q1 2023 after selling out during the quarter.
Capital Advisors Ltd sold 43 Altimmune shares in Q1 2023, an estimated $1K.
Capital Advisors Ltd first reported a position in Altimmune in Q2 2022 and held it in 3 quarters.
Capital Advisors Ltd's Altimmune position peaked at $1K in Q4 2022.
132 funds tracked by Wall St. Rank held Altimmune as of Q1 2023.

Based on Capital Advisors Ltd's 13F filing for Q1 2023, filed 3 May 2023.